Cardiovascular human organ-on-a-chip platform for disease modeling, drug development, and personalized therapy

Astha Khanna; Beu P Oropeza; Ngan F Huang

doi:10.1002/jbm.a.37602

Cardiovascular human organ-on-a-chip platform for disease modeling, drug development, and personalized therapy

J Biomed Mater Res A. 2024 Apr;112(4):512-523. doi: 10.1002/jbm.a.37602. Epub 2023 Sep 5.

Authors

Astha Khanna¹, Beu P Oropeza^{2

3

4}, Ngan F Huang^{2

3

4

5}

Affiliations

¹ Graver Technologies, Newark, New Jersey, USA.
² Department of Cardiothoracic Surgery, Stanford University, Stanford, California, USA.
³ Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA.
⁴ Center for Tissue Regeneration, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
⁵ Department of Chemical Engineering, Stanford University, Stanford, California, USA.

PMID: 37668192
PMCID: PMC11089005 (available on 2025-04-01)
DOI: 10.1002/jbm.a.37602

Abstract

Cardiovascular organ-on-a-chip (OoC) devices are composed of engineered or native functional tissues that are cultured under controlled microenvironments inside microchips. These systems employ microfabrication and tissue engineering techniques to recapitulate human physiology. This review focuses on human OoC systems to model cardiovascular diseases, to perform drug screening, and to advance personalized medicine. We also address the challenges in the generation of organ chips that can revolutionize the large-scale application of these systems for drug development and personalized therapy.

Keywords: biomaterials; cardiovascular; organ-on-a-chip; organoid; stem cell.

Publication types

Review
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Drug Development
Drug Evaluation, Preclinical / methods
Humans
Lab-On-A-Chip Devices*
Microphysiological Systems*
Tissue Engineering / methods

Abstract

Publication types

MeSH terms

Grants and funding